{
    "nctId": "NCT04505826",
    "briefTitle": "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer",
    "officialTitle": "A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 153,
    "primaryOutcomeMeasure": "Dose Limiting Toxicities (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease\n* Must not have received prior oral endocrine therapy \\< 2 weeks prior to first dose\n* Must not have received prior, chemotherapy in 2 weeks or within 5 half-lives whichever is earlier, antibody therapy within 4 weeks or investigational therapy within 4 weeks or 5 half-lives whichever is earlier, prior to the first dose\n* Adequate hepatic function\n* Adequate renal function\n* Normal coagulation panel\n* Willingness to use effective contraception\n\nExclusion Criteria:\n\n* Gastrointestinal disease\n* Significant renal disease\n* Significant cardiovascular disease\n* Significant ECG abnormalities\n* Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial therapy)\n* Pregnancy or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}